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ABSTRACT
Snakebite envenomings represent a neglected public health issue in many parts of the
rural tropical world. Animal-derived antivenoms have existed for more than a hundred
years and are effective in neutralizing snake venom toxins when timely administered.
However, the low immunogenicity of many small but potent snake venom toxins
represents a challenge for obtaining a balanced immune response against the medically
relevant components of the venom. Here, we employ high-throughput sequencing of
the immunoglobulin (Ig) transcriptome of mice immunized with a three-finger toxin
and a phospholipase A2 from the venom of the Central American coral snake,Micrurus
nigrocinctus. Although exploratory in nature, our indicate results showed that only low
frequencies of mRNA encoding IgG isotypes, the most relevant isotype for therapeutic
purposes, were present in splenocytes of five mice immunized with 6 doses of the two
types of toxins over 90 days. Furthermore, analysis of Ig heavy chain transcripts showed
that no particular combination of variable (V) and joining (J) gene segments had been
selected in the immunization process, as would be expected after a strong humoral
immune response to a single antigen. Combined with the titration of toxin-specific
antibodies in the sera of immunized mice, these data support the low immunogenicity
of three-finger toxins and phospholipases A2 found in M. nigrocinctus venoms, and
highlight the need for future studies analyzing the complexity of antibody responses to
toxins at the molecular level.
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INTRODUCTION
Snakebite envenomings represent a major public health concern in tropical regions of the
world (Williams et al., 2011). Despite emerging discoveries that may one day pave the way
for novel biotechnology-based antivenoms (reviewed by Laustsen et al., 2016a; Laustsen
et al., submitted), animal serum-derived antivenoms remain the cornerstone of snakebite
envenoming treatment (Gutiérrez et al., 2011). Production of antivenom is challenged
by a large variation in immunogenicity of many key snake venom toxins resulting in
unpredictable immune responses in production animals (Cook et al., 2010; Guidolin et al.,
2010). It has been shown that many of the immunogenic venom components are in fact
not important for toxicity (Antúnez et al., 2010; Gutiérrez et al., 2009; Laustsen et al., 2015),
and conversely, that some highly toxic venom components, such as α-neurotoxins (both
short and long neurotoxins), phospholipases A2, and P-I snake venom metalloproteinases
may be poorly immunogenic (Schottler, 1951; Gutiérrez et al., 2009; Chotwiwatthanakun
et al., 2001; Ownby & Colberg, 1990; Judge et al., 2006; Wong, Tan & Tan, 2016; Tan et al.,
2016; Leong et al., 2015; Tan et al., 2015). Combined, this creates a challenge for antivenom
production, since the goal of obtaining an antivenom with a strong, yet balanced response
against all the medically relevant toxins becomes a complex endeavor.
Coral snakes (genera Micrurus, Leptomicrurus, and Micruroides) are, together with the
sea snake Hydrophis (Pelamis) platura, the representatives of the snake family Elapidae in
the Americas, comprising approximately 85 species (Campbell & Lamar, 2004; the Reptile
Database—www.reptile-database.org). AlthoughMicrurus species are only responsible for
about 1-2% of snakebite cases in this continent, roughly corresponding to 750 to 1000
cases per year, envenomings by these snakes can be fatal if not treated properly and timely
(Warrell, 2004; Gutiérrez et al., 2016; Bucaretchi et al., 2016). Envenomings resulting from
coral snakebites are predominantly associated with descending neuromuscular paralysis,
which may end in respiratory arrest (Warrell, 2004; Bucaretchi et al., 2016).
Production of antivenoms against Micrurus snakes is particularly challenging, as (a) it
is very difficult to maintain coral snakes in captivity (Chacón et al., 2012); (b) the majority
of Micrurus species provide a very low yield of venom, implying that the collection of the
quantities of venom required for horse immunization and quality control testing demands
the ‘milking’ of many specimens (Chacón et al., 2012; Bolaños, 1972); and (c) there is a
variable extent of immunological cross-recognition between venoms from coral snakes of
different species; hence, antivenoms raised against some species are not always effective
in the neutralization of venoms of other species (Bolaños, Cerdas & Abalos, 1978; Tanaka
et al., 2016). As a result, only a few laboratories manufacture Micrurus antivenoms, and
several countries where these snakes inhabit completely lack this therapeutic resource,
e.g., Venezuela, Ecuador, Peru, Bolivia, the Guyanas, and Paraguay, which severely limits
the clinical management of these accidents.
Knowledge on the composition of the venoms ofMicrurus species has increased steadily
over the last years, as a consequence of proteomic characterizations (reviewed by Lomonte
et al., 2016b). Two main venom phenotype patterns have been identified, i.e. venoms rich
in neurotoxins of the three-finger toxin (3FTx) family, and venoms rich in phospholipases
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A2 (PLA2s) (Fernández et al., 2015). In addition to these two main protein families, other
minor components of these venoms include L-amino acid oxidases, serine proteinases,
metalloproteinases, nerve growth factor, C-type lectin-like proteins, Kunitz-type inhibitors,
among others (Fernández et al., 2011; Fernández et al., 2015; Corrêa-Netto et al., 2011;
Lomonte et al., 2016a; Sanz et al., 2016; Rey-Suárez et al., 2011; Rey-Suárez et al., 2016). In
some cases, the toxins playing the main role in overall toxicity have been identified, these
being 3FTxs and PLA2s (Rey-Suárez et al., 2012; Vergara et al., 2014; Fernández et al., 2015;
Castro et al., 2015; Ramos et al., 2016).
The limited immunogenicity of the highly toxic PLA2s and 3FTxs (Fernández et
al., 2011; Rosso et al., 1996; Alape-Girón et al., 1996) represents another difficulty in
production ofMicrurus antivenom, since it thwarts the goal of raising a balanced immune
response against these medically relevant toxins. In order to further explore how these
toxins interact with the mammalian immune system, we chose a mouse model and
employed an NGS approach using the AbSeqTM technology developed by AbVitro (now
Juno Therapeutics, https://www.junotherapeutics.com), based on Illumina sequencing
(Fig. 1). The methodology was utilized to sequence immunoglobulin (Ig) encoding mRNA
transcripts from splenic B-lymphocytes in mice subjected to immunization with either
a 3FTx or a PLA2 toxin from the venom of M. nigrocinctus (Central American coral
snake). By this approach, the transcription levels of different immunoglobulin isotypes and
dominant clones of B-lymphocytes with a particular usage of V (variable) and J (joining)
gene segments can be determined for Ig heavy chain transcripts. This methodology has
previously been employed for investigating B-cell populations in autoimmune (Stern et
al., 2014) or infectious diseases (Tsioris et al., 2015; Di Niro et al., 2015), for example. By
employing the AbSeqTM high-throughput approach, we explore, for the first time, the Ig
transcriptome including VJ usage patterns in individual animals subjected to immunization
with two relevant toxin classes of elapid snakes. Although exploratory in its nature and
somewhat limited by a small sample size, this study thus provides novel insight into the
humoral response of mice immunized with 3FTx or PLA2 toxins and highlights important
challenges of raising antibodies against poorly immunogenic toxins.
MATERIALS AND METHODS
Snake venom and toxins
Venom from M. nigrocinctus was obtained from a pool of more than 50 adult specimens
collected in the Central Pacific region of Costa Rica, kept at the serpentarium of Instituto
Clodomiro Picado, Universidad de Costa Rica. The snakes were not collected for this study,
but belong to Instituto Clodomiro Picado, where their venoms are routinely used for the
production of antivenom, wherefore a field permit was not necessary. Venom extraction is
performed every four months (Chacón et al., 2012). The venom was lyophilized and stored
at −20 ◦C.
Fractionation of the venom was performed by RP-HPLC on a C18 column (4.6 × 250
mm, 5 µm particle diameter; Supelco) as previously described (Fernández et al., 2011).
In brief, 2 mg of venom dissolved in 200 µL of water containing 0.1% trifluoroacetic
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Figure 1 Schematic overview of the experimental strategy. Following extraction from the snakes,
venom is fractionated by HPLC, and the fractions of interest are used for immunization of rodents.
Upon completion of the immunization protocol, the rodents are sacrificed and RNA is extracted and
subjected to the AbSeq protocol (see ‘Materials and Methods’), whereby the RNA is reverse transcribed
and barcoded, allowing for correct pairing of VH and VL chains after DNA sequencing.
acid (TFA; solution A) were separated at 1 mL/min in an Agilent 1200 chromatograph
monitored at 215 nm, applying a gradient towards solution B (acetonitrile, containing
0.1% TFA): 0% B for 5 min, 0–15% B over 10 min, 15–45% B over 60 min, 45–70% B over
10 min, and 70% B over 9 min. Fractions of interest (the major components of the venom,
belonging to the 3FTx (lethal) and PLA2 (myotoxic) protein families) were collected
manually, dried in a vacuum centrifuge, and identified by trypsin digestion followed by
MALDI-TOF/TOFmass spectrometry (Fernández et al., 2011). Proteins were redissolved in
water and their concentrations were estimated on the basis of their absorbance at 280 nm,
using a NanoDrop (Thermo) instrument.
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Immunization of mice
Three female CD-1 mice (16–18 g) from Instituto Clodomiro Picado were immunized
with a three-finger toxin (3FTx), and two with a phospholipase A2 (PLA2), respectively.
These correspond to fractions #3 (∼P80548) and #30 (∼P81166/P81167) described in
the previous proteomic characterization of this venom (Fernández et al., 2011). All toxin
doses were injected by the intraperitoneal route. The priming dose was 1 µg emulsified in
Freund’s complete adjuvant, followed by five booster doses injected in physiological saline
without adjuvant, at days 15 (1 µg), 43 (2 µg) 63 (4 µg), and 83 (6 µg for the 3FTx and 8 µg
for the PLA2). At day 90, after obtaining a blood sample for monitoring of the antibody
response by enzyme-immunoassay, mice were euthanized by CO2 inhalation. Their spleens
were immediately removed, cut in small pieces, and disaggregated over a stainless steel
mesh to obtain splenocytes. These cell suspensions were aliquoted in RNAlater R© solution
(Thermo) and shipped within 24 h to AbVitro, at room temperature, for subsequent
molecular studies. The use of animals for these experiments followed the ethical guidelines
of theComité Institucional para el Uso y Cuido de Animales (CICUA), Universidad de Costa
Rica, with the approval number 82-08.
Enzyme-immunoassay (ELISA)
In order to evaluate the individual antibody responses of the mice, wells in MaxiSorp
96-well plates (NUNC, Roskilde, Denmark) were coated overnight with 1 µg of either
3FTx or PLA2, dissolved in 100 µL PBS (0.12 M NaCl, 0.04 M sodium phosphate, pH 7.2).
Wells were washed five times with PBS and blocked by adding 100 µL PBS containing 2%
(w:v) bovine serum albumin (BSA; Sigma), and incubated at room temperature for 1 h.
Plates were then washed five times with PBS. Serial dilutions of serum from each mouse
were prepared in PBS + 2% BSA and 100 µL was added to each well, in triplicates, and
incubated overnight at 4 ◦C. Normal mouse serum, run simultaneously under identical
conditions was used as a control for background. Plates were then washed five times with
PBS, followed by the addition of 100 µL of a 1:3,000 dilution of anti-mouse IgG (whole
molecule) antibodies conjugated to alkaline phosphatase, in PBS + 1% BSA. The plates
were incubated for 2 h, and then washed five times with FALC buffer (0.05 M Tris, 0.15 M
NaCl, 20 µMZnCl2, 1 mMMgCl2, pH 7.4). Development of color was attained by addition
of 100 µL p-nitrophenyl phosphate (1 mg/mL in 9.7% v/v diethanolamine buffer, pH 9.8)
and absorbances at 405 nm were recorded (Multiskan FC; Thermo Scientific).
Assessment of mRNA quality
Assessment of RNA quality was performed using Agilent’s TapeStation according to the
manufacturers protocol and algorithm to calculate RINe scores (http://www.agilent.com/
cs/library/technicaloverviews/public/5990-9613EN.pdf).
Library preparation and high-throughput sequencing of B-cell
receptors
The method for high-throughput sequencing of the B-cell repertoire was performed as
described elsewhere (Di Niro et al., 2015; Tsioris et al., 2015). Briefly, RNA was reverse-
transcribed into cDNA using a biotinylated oligo dT primer. An adaptor sequence was
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added to the 3′ end of all cDNA, which contains the Illumina P7 universal priming site
and a 17-nucleotide unique molecular identifier (UMI). Products were purified using
streptavidin-coated magnetic beads followed by a primary PCR reaction using a pool of
primers targeting the IGHA, IGHD, IGHE, IGHG, IGHM, IGKC and IGLC regions, as
well as a sample-indexed Illumina P7C7 primer. The immunoglobulin-specific primers
contained tails corresponding to the Illumina P5 sequence. PCRproducts were then purified
using AMPure XP beads. A secondary PCR was then performed to add the Illumina C5
clustering sequence to the end of the molecule containing the constant region. The number
of secondary PCR cycles was tailored to each sample to avoid entering plateau phase, as
judged by a prior quantitative PCR analysis. The final products (reverse-transcribed UTR
+ VDJ + partial—Cexon segments of the transcripts of the immunoglobulin chains, plus
molecular barcode, Illumina multiplexing barcode, and Illumina sequencing adapters)
were purified, quantified with Agilent TapeStation and pooled in equimolar proportions,
followed by high-throughput paired-end sequencing on the Illumina MiSeq platform. For
sequencing, the Illumina 600 cycle kit was used with the modifications that 325 cycles was
used for read 1, 6 cycles for the index reads, 300 cycles for read 2 and a 10% PhiX spike-in
to increase sequence diversity.
VJ repertoire sequencing data analysis
MiSeq reads were demultiplexed using Illumina software, and processed with the pRESTO
toolsuite (Vander Heiden et al., 2014) as following: Positions with less than Phred quality
5 were masked with Ns. Isotype-specific primers and molecular barcodes (UIDs or UMIs)
were identified in the amplicon and trimmed, using pRESTO MaskPrimers-cut. A read 1
and read 2 consensus sequencewas generated separately for eachmRNA from reads grouped
by unique molecular identifier, which are PCR replicates arising from the same original
mRNA molecule of origin. UMI read groups were aligned with MUSCLE (Edgar, 2004),
and pRESTOwas used to BuildConsensus, requiring≥60% of called PCR primer sequences
agree for the read group, maximum nucleotide diversity of 0.1, using majority rule on indel
positions, and masking alignment columns with low posterior (consensus) quality. Paired
end consensus sequences were then stitched in two rounds. First, ungapped alignment of
each read pair’s consensus sequence termini was optimized using a Z-score approximation
and scored with a binomial p-value as implemented in pRESTO AssemblePairs-align. For
read pairs failing to stitch this way, stitching was attempted using the human BCR germline
V exons to scaffold each read prior to stitching or gapped read-joining, using pRESTO’s
AssemblePairs-reference. Positions with posterior consensus quality less than Phred 5 were
masked again with Ns. Each mRNA was annotated for V, D, J germline gene of origin,
productivity, and CDR3 region using igblastn (Ye et al., 2013). Igblast output was parsed
and analyzed with custom scripts as described below (proprietary to AbVitro (now Juno
Therapeutics)) and visualized with R (R Core Team, 2014). Briefly, clones were defined
using a conservative approach, grouping mRNAs from the same V and J germline gene
of origin and having the same isotype and CDR3 nucleotide sequence. Non-productive
rearrangements (as predicted by Igblast) were excluded from the analysis. Within each
sample, clones were ranked by abundance (mRNAs/clone) and plotted to highlight the
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most expanded binding motifs. To examine preferences for V–J usage common across
mice exposed to the same toxin, clones were grouped into larger bins that each encompass
a single V gene-J gene combination, but all isotypes and CDR3s.
In silico epitope predictions
The sequences of selected toxin components in the two venom fractions used for
immunization were obtained from the UniProtKB database (http://www.uniprot.org)
and linear parts of B-cell epitopes were predicted using the Bepi-Pred 1.0 server (Larsen,
Lund & Nielsen, 2006) using 0.9 as Threshold to obtain a sensitivity of 0.25 and Specificity
of 0.91. As no experimental structures were available, homology models were build based
CPHmodels 3.2 (Nielsen et al., 2010) and the pdb-files were submitted to DiscoTope 2.0
(Kringelum et al., 2012) using 0.5 as Threshold to obtain a sensitivity of 0.23 and Specificity
of 0.90.
RESULTS AND DISCUSSION
Three-finger toxins (3FTx) and phospholipase A2s (PLA2) are the two most abundant
toxin families in the venom of M. nigrocinctus (Fernández et al., 2011), and generally they
are the two snake toxin families which have been most investigated (Laustsen et al., 2016a).
In the venom of M. nigrocinctus these toxins cause neuromuscular paralysis, owing to a
combination of pre- and post-synaptic actions, and myotoxicity, providing the venom
with its high toxicity (Rosso et al., 1996; Alape-Girón et al., 1996). In previous studies it was
observed that 3FTxs and PLA2s were recognized more weakly than larger proteins from
this venom, by a therapeutic equine antivenom (Fernández et al., 2011). Despite their low
immunogenicity, it was possible to raise an antibody response against both toxins in four
out of five mice, although high variation in the antibody titer was observed (Fig. 2). Mice
immunized with PLA2 had a higher antibody titer than mice immunized with the 3FTx, in
agreement with the higher molecular mass of the former.
Assessment of the mRNA from harvested mouse splenocytes indicated that it was of
sufficient quality to proceed to sequencing (RINe scores between 5.2 and 6.4). A high-
throughput sequencing approach (AbSeqTM) was employed to investigate transcription
levels of Ig isotypes and the usage of V and J gene segments for heavy chain assembly in
mice that were immunized with a 3FTx or a PLA2. Investigation of the 50 most frequent
VJ combinations for the immunized mice did not, however, result in identification of
a dominant combination, as the VJ usage was found to be similar across all samples
(Fig. 3). This finding suggests that the generated antibody responses might be diverse and
that multiple specific antibodies with low abundance are generated in each mouse.
Looking at the sequences of all mRNA transcripts encoding heavy chain variable
domain (VH) clones across each sample, we were able to find shared VH clones with
similar relative abundances in either the PLA2-immunized or the 3FTx-immunized mice
(Fig. 4). In comparison, almost no VH clones were shared between mice immunized with
different toxins (Fig. 5). This implies that the immunization procedure did indeed elicit
specific, but different responses dependent on whether PLA2s or 3FTxs were employed
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Figure 2 ELISA titrations of serum antibodies againstM. nigrocinctus PLA2 or 3FTx in mice following
a 90-day immunization protocol. Two mice were immunized with PLA2, and three were immunized with
3FTx. Plates were coated with either PLA2 or 3FTx, and antibodies were detected as described in ‘Materials
and Methods’.
for immunization. The relatively high number of VH clones found in both of the PLA2-
immunized mice (Fig. 4A) compared to lower number of VH clones found across the three
3FTx-immunized mice (Figs. 4B–4D) further indicate that immunization with PLA2s is
more prone to give rise to antibodies transcribed in similar quantities. Also, an intermediate
number of similar VH clones was found in both the PLA2-1 and 3FTx-3 samples (Fig. 5E),
even though the correlation in relative abundance was not equally pronounced. This is
likely explained by the fact that the majority of VH clones found in both PLA2-immunized
mice are not expected to be specific towards the toxins, but instead are likely to be directed
against other (environmental) antigens that the mice have encountered throughout their
life.
The AbSeqTM antibody sequencingmethodology is capable of determining the Ig isotype
of the identified VH clones. The coloring of the VH clones in Figs. 4 and 5 reveals that a
large number of the most abundant VH clones present in the mice are of the IgA isotype,
which was confirmed by further investigation of all mRNA transcripts from the splenocytes
(Fig. 6). This is surprising, as IgG is known to be the dominant immunoglobulin class in
mouse blood after the response to T-dependent protein antigens. The observation could
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Figure 3 Comparison of the relative abundance of mRNA for the 50 most abundant VJ combinations
for the mouse 3FTx-3 andmouse PLA2-2 showing VJ usage to be similar across samples. Similar VJ us-
age patterns were observed for other pairs of immunized mice.
Figure 4 Relative abundance of unique VH clone transcripts compared between samples. A large
group of VH transcripts are found in similar abundance in different mice immunized with the same
toxin. (A) Comparison between mouse PLA2-1 and PLA2-2, (B) Comparison between mouse 3FTx-1 and
3FTx-2, (C) Comparison between mouse 3FTx-1 and 3FTx-3, (D) Comparison between mouse 3FTx-2
and 3FTx-3.
Laustsen et al. (2017), PeerJ, DOI 10.7717/peerj.2924 9/18
Figure 5 Relative abundance of unique VH clone transcripts compared between samples. Only few VH
transcripts are found in similar abundance in more than one mouse, when mice immunized with differ-
ent toxins are compared. (A) Comparison between mouse PLA2-1 and 3FTx-1, (B) Comparison between
mouse PLA2-2 and 3FTx-1, (C) Comparison between mouse PLA2-1 and 3FTx-2, (D) Comparison be-
tween mouse PLA2-2 and 3FTx-2, (E) Comparison between mouse PLA2-1 and 3FTx-3, (F) Comparison
between mouse PLA2-2 and 3FTx-3.
possibly be explained by differences in expression levels due to different translation rates and
half-lives of mRNA transcripts encoding different immunoglobulin isotypes. All approved
antibody-based therapies on the market are based on IgGs (Walsh, 2014), which are also
the desired isotype for antivenoms. In immunized horses for antivenom production, two
isotypes of IgG are largely responsible for the neutralization of toxic effects in the case of
viperid snake venoms (Fernandes et al., 2000). However, analysis of the transcripts obtained
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Figure 6 Overview of total mRNA transcripts encoding different immunoglobulin isotypes from the
immunized mice (normalized).Numbers above each bar represents the mRNA count in each sample.
from the immunized mice revealed only a low percentage of IgG transcripts, as compared
to the transcripts for other Igs (Figs. 4–6). With the acknowledgement of the small sample
size employed in this study, this finding may indicate a difficulty in raising potent IgG
antibodies against both 3FTxs and PLA2s in rodents. If similar difficulty is present in
horses, this may therefore have implications for antivenom production. Our results may
further suggest that the immune response is slightly lower against 3FTxs than for PLA2s
based on the lower abundance of IgG transcripts in mice immunized with 3FTx (Fig. 6).
Taken together with the results from the ELISA assay (Fig. 2) and the observation that
immunization with PLA2s is more prone to give rise to similar Ig transcripts (Fig. 4A vs.
Figs. 4B–4D), we suggest that the PLA2 toxins may possibly be slightly more immunogenic
than the 3FTx, although neither toxin seems to have high immunogenicity. The underlying
reason for this could possibly be due to the smaller molecular size of 3FTx compared to
PLA2s, or that PLA2s may contain distinct epitopes better capable of eliciting an adaptive
immune response than 3FTxs. Predictions of possible B-cell epitopes using the protein
sequences and BepiPred 1.0 (Larsen, Lund & Nielsen, 2006) or DiscoTope 2.0 (Kringelum et
al., 2012) with structural models of the investigated toxins as input do not indicate a major
difference in the bare number of possible epitopes. However, the suggested difference
in immunogenicity is further indicated by the fact that only two IgG-encoding mRNA
transcripts are found in the top 20 most abundant Ig-encoding mRNA transcripts for only
one out of three of the 3FTx-immunized mice. In comparison, six and nine of the top
20 mRNA transcripts for mice immunized with PLA2s encode the IgG isotype (Fig. 7). It
would be interesting to assess whether the immune response of horses against these elapid
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Figure 7 The 20 most abundant VH clone transcripts and their corresponding isotypes in each immu-
nized mouse based on their fraction of total immunoglobulin mRNA.
venom toxins is also characterized by a low proportion of IgG—a finding that would have
evident implications for antivenommanufacture, as IgG has been shown to be the antibody
isotype of therapeutic value (Fernandes et al., 2000). However, this is beyond the scope of
this exploratory study.
CONCLUDING REMARKS AND OUTLOOK
In addition to demonstrating the utility of high-throughput sequencing technology,
AbSeqTM, for investigation of immune responses in animals immunized with snake
venom toxins, the exploratory findings presented here may indicate possible difficulties
in obtaining an IgG response against the medically important toxins of the 3FTx and
PLA2 families from M. nigrocinctus. Given that these proteins play key toxic roles
in envenomings by elapid snakes, this underlines a drawback of current antivenom
production based on immunized animal serum, since IgG has been shown to be the
antibody isotype of therapeutic value (Fernandes et al., 2000). Although based on a small
exploratory sample size, these findings therefore contribute to the understanding of snake
toxin immunogenicity and indicate the possible difficulty in obtaining balanced immune
responses in animals during the immunization process.
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